Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Iovance Biotherapeutics IOVA shares are surging on Tuesday following the announcement of positive early data from a pilot ...
ascopubs.org

Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
MedPage Today

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE ...
Healio

Neoadjuvant immunotherapy may improve sarcoma outcomes

Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...
Investing.com Australia

Iovance stock surges 32% on positive sarcoma trial data

Investing.com -- Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares jumped 32% Tuesday following positive early data from a pilot clinical trial of lifileucel in patients with advanced undifferentiated ...
MedPage Today

Chemo-ICI Combo Promising in Soft Tissue Sarcoma

A combination of eribulin (Halaven) and pembrolizumab (Keytruda) offered promising results in patients with metastatic soft tissue sarcomas that were sensitive to immune checkpoint inhibition (ICI), a ...